<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Pharmacophore</journal-id>
      <journal-id journal-id-type="publisher-id">pharmacophorejournal.com</journal-id>
      <journal-id journal-id-type="publisher-id">Pharmacophore</journal-id>
      <journal-title-group>
        <journal-title>Pharmacophore</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2229-5402</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">pharmacophorejournal.com-6794</article-id>
      <article-id pub-id-type="doi">10.51847/E1l0KDSnG1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cytotoxicity of Galantamine Peptide Esters Against Hela Cell Lin</article-title>
      </title-group>
                  <pub-date pub-type="epub">
        <day>03</day>
        <month>03</month>
        <year>2024</year>
      </pub-date>
      <volume>14</volume>
      <issue>3</issue>
      <fpage>131</fpage>
      <lpage>138</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Pharmacophore
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>In this study, the cytotoxic potential of newly synthesized peptide esters of Galantamine, namely GAL-VAL and GAL-LEU, was investigated against the human cervical adenocarcinoma cell line (HeLa) across a range of concentrations spanning from 1.875µM to 30µM. Notably, GAL-LEU demonstrated significant efficacy in suppressing HeLa cells, particularly at a concentration of 30 µM, where it elicited an impressive 86.81% reduction in cell viability. This effect was corroborated by a corresponding index of cell viability of 13.19%. Further analysis revealed that GAL-LEU possessed a substantially lower IC50 value of 23.63 µM compared to GAL-VAL, which exhibited an IC50 value of 31.95µM. These findings highlight the pronounced cytotoxic effects of both esters on the HeLa cell line, with GAL-LEU exhibiting superior antiproliferative potency. The results of this investigation suggest the potential utility of GAL-VAL and GAL-LEU as promising candidates warranting further exploration in cancer therapeutics, particularly in the context of addressing cervical adenocarcinoma.</p>
      </abstract>
      <kwd-group>
              </kwd-group>
    </article-meta>
  </front>
</article>